Vanguard ESG US Stock ETF (ESGV) Stock
Key stats
- Market cap
- $6.24B
- Volume
- Loading
- 52-week high
- $138.88
- 52-week low
- $108.18
Source: third-party data provider, as of November 13, 2026
Recent news

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy
ESGV

Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details
Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details
ESGV

Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3
Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3
ESGV

Here Are 6 ETFs Bill Gates Might Endorse for Everyday Investors
Here Are 6 ETFs Bill Gates Might Endorse for Everyday Investors
ESGV
Technical indicators
- RSI 14
- 49.53
- MACD 12/26/9
- -1.01
- EMA 9 of MACD
- -0.90
- MACD histogram
- -0.11
- SMA 50
- $135.37
- Price below SMA 50
- EMA 50
- $134.61
- Price below EMA 50
- SMA 200
- $128.71
- Price above SMA 200
- EMA 200
- $129.09
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy
ESGV

Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details
Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details
ESGV

Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3
Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3
ESGV

Here Are 6 ETFs Bill Gates Might Endorse for Everyday Investors
Here Are 6 ETFs Bill Gates Might Endorse for Everyday Investors
ESGV

Six Months Into 2024, This Vanguard ESG Fund Trailed the S&P 500. But Don't Panic If You Own It.
Six Months Into 2024, This Vanguard ESG Fund Trailed the S&P 500. But Don't Panic If You Own It.
ESGV

Can Vanguard ESG U.S. Stock ETF Be Your Only Stock Holding?
Can Vanguard ESG U.S. Stock ETF Be Your Only Stock Holding?
ESGV

ETFs Which Have The Best Chance Of Outperforming For The Rest Of 2024
ETFs Which Have The Best Chance Of Outperforming For The Rest Of 2024
ESGV

Want to Own All the "Magnificent Seven" Stocks? Buy One of These Vanguard ETFs.
Want to Own All the "Magnificent Seven" Stocks? Buy One of These Vanguard ETFs.
ESGV

ESGV: An Ethical ETF Outperforming In 2023
ESGV: An Ethical ETF Outperforming In 2023
ESGV

The Year's Top 3 ESG ETFs as of August 2023
The Year's Top 3 ESG ETFs as of August 2023
ESGV
About Vanguard ESG US Stock ETF
The Vanguard ESG US Stock ETF seeks to track the performance of the FTSE US All Cap Choice Index and is comprised of large-, mid-, and small-capitalization stocks. The holdings are screened for certain environmental, social, and corporate governance (ESG) criteria and specifically excludes stocks of certain companies in the following industries: adult entertainment, alcohol, tobacco, weapons, fossil fuels, gambling, and nuclear power. It also excludes stocks of certain companies that do not meet standards of U.N. global compact principles and companies that do not meet certain diversity criteria.
Fundamentals
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 49.53
- MACD 12/26/9
- -1.01
- EMA 9 of MACD
- -0.90
- MACD histogram
- -0.11
- SMA 50
- $135.37
- Price below SMA 50
- EMA 50
- $134.61
- Price below EMA 50
- SMA 200
- $128.71
- Price above SMA 200
- EMA 200
- $129.09
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.0 | +5.0 | ||||||||||
| 2022 | -7.6 | -3.8 | +4.6 | -10.2 | -1.8 | -7.2 | +8.5 | -4.2 | -9.7 | +4.4 | +5.8 | -6.9 |
| 2023 | +8.3 | -3.5 | +3.6 | +0.9 | +1.8 | +5.2 | +3.3 | -1.7 | -5.6 | -2.8 | +9.1 | +4.4 |
| 2024 | +2.2 | +4.0 | +1.5 | -4.6 | +5.3 | +3.5 | +0.8 | +3.7 | +4.3 | +0.3 | +6.1 | -2.8 |
| 2025 | +3.2 | -1.6 | -5.2 | -0.8 | +5.9 | +4.7 | +2.3 | +4.2 | +4.2 | +2.1 | -0.4 | +0.3 |
| 2026 | +0.5 | -2.6 | -5.7 | +11.0 | +6.1 | -1.8 | -0.2 | +1.6 | +0.5 | -2.2 | +1.5 |
Corporate actions
Upcoming
No upcoming corporate actions for ESGV




